

**U.S. Food and Drug Administration
Center for Tobacco Products**

**OMB Control No. 0910-0810
Exp. Date: 10/31/2021**

**Monthly Monitoring Study
Supporting Statement: Summary**

- The goal of this study is to monitor youth and young adult perceptions and emerging trends in brand and device use for vaping products and little cigar and cigarillo (LCC) use. We will focus on these two target audiences: (1) youth and young adults ages 15 to 24 years in the United States who are susceptible to, or currently use vaping products, and (2) youth and young adults ages 15 to 24 years who are susceptible to, or currently use LCCs.
- RTI will conduct online surveys with youth and young adults in the United States recruited through social media (i.e., Facebook, Instagram) to monitor perceptions about vaping products, LCCs, and other emerging tobacco products. Once approvals are received, we will begin data collection for a national, online self-administered social media survey of approximately 1,500 youth per month, ages 15-17, and young adults ages 18-24. The survey will be repeated with a new cross-sectional sample approximately monthly over a period of 12 months.
- We will also administer a youth and young adult survey on LCCs, an online survey through social media (i.e., Facebook, Instagram) to monitor trends in LCC use among youth and young adults ages 15 to 24 years. Once approvals are received, we will begin data collection for a national, online self-administered social media survey of approximately 750 youth per quarter, ages 15-17, and young adults ages 18-24. The survey will be repeated with a new cross-sectional sample approximately four times a year. The results of the vaping surveys and the LCC surveys will be used to inform specified recommendations around the U.S. Food and Drug Administration Center for Tobacco Products' (CTP) public education programs' impact and effectiveness in reducing tobacco-related death and disease.
- Results of the survey will help CTP better understand-
 - the trends in brand and device use for vaping products among youth and young adults ages 15 to 24 years in the United States.
 - the reactions to proposed messages for media campaigns related to vaping products among youth and young adults ages 15 to 24 years in the United States.
 - the trends in little cigar and cigarillo (LCC) use among youth and young adults ages 15 to 24 years in the United States.
 - the reactions to proposed messages for media campaigns related to LCCs among youth and young adults ages 15 to 24 years in the United States.
- **REQUESTED APPROVAL DATE: 11/20/2020**

Study Materials (attached):

Attachment 1. Screener_Survey -- ENDS

Attachment 2. Screener_Survey -- LCC

Attachment 3. Youth Assent -- ENDS

Attachment 4. Youth Assent -- LCC

Attachment 5. Young Adult Consent -- ENDS

Attachment 6. Young Adult Consent -- LCC

Monthly Monitoring Study
OMB Control No. 0910-0810
Supporting Statement

A. JUSTIFICATION

1. Circumstances Making the Collection of Information Necessary

In support of the U.S. Food and Drug Administration’s (FDA) efforts to refresh campaign messaging, the Center for Tobacco Products (CTP) will conduct a quantitative study to inform the development of appropriate messaging for FDA’s The Real Cost campaign. In 2019, 27.5% of high school students reported vaping and 31.2 % reported use of any tobacco product in the past 30 days (Wang et al., 2019). From 2017 to 2018, reported prevalence of current and daily vaping among young adults ages 18 – 24 years increased by 46.2% (Dai & Leventhal, 2019) and 38% of young adults were current users of a tobacco product in 2013 and 2014 (Kasza et al., 2017). As a way to reduce the enormous public health burden of tobacco, the Family Smoking Prevention and Tobacco Control Act has given the FDA the authority to take action to protect children, encourage smokers to quit, and reduce tobacco-related disease and death. The law also enables FDA to educate the public, especially young people, about the dangers of tobacco products. Research shows that public education mass media campaigns can be used to change attitudes and beliefs about tobacco use and reduce smoking prevalence. In fact, the Centers for Disease Control and Prevention (CDC) considers mass media campaigns to be a “best practice” for tobacco control.

In an effort to inform specified recommendations around FDA’s public education programs’ impact and effectiveness in reducing tobacco-related death and disease, more research is needed to understand the trends in brand and device choices so that the FDA can develop new media campaign messages related to tobacco and vaping products that resonate with youth and young adults ages 15 to 24 years old in the United States. The purpose of this Monthly Monitoring study is to collect primary data to monitor youth and young adult perceptions and emerging trends in brand and device use for vaping products and little cigar and cigarillo (LCC) use.

The study will be conducted using web-based surveys that are self-administered on personal computers or web enabled mobile devices. The study will use an online survey to target up to 18,000 youth and young adults ages 15 to 24 years to monitor perceptions about vaping products, LCCs, and other emerging tobacco products, and up to 3,000 youth and young adults ages 15 to 24 years to monitor trends in LCC use. Both studies will include questions about marijuana use to allow the study team to differentiate between use of current and emerging tobacco products and marijuana, which can be used in vaping and LCC products. The survey will take approximately 12 minutes to complete per participant. This survey will ask participants to provide feedback on tobacco use as well as randomly selected facts and then answer questions about their knowledge, attitudes, and beliefs about these facts.

2. Purpose and Use of the Information

RTI will conduct online surveys with youth and young adults in the United States recruited through social media (i.e., Facebook, Instagram) to monitor perceptions about vaping products, LCCs, and other emerging tobacco products. As soon as approvals are received, we will begin data collection for a national, online self-administered social media survey of approximately 1,500 youth per month, ages 15-17, and young adults ages 18-24. The survey will be repeated with a new cross-sectional sample approximately monthly over a period of 12 months.

We will also administer a youth and young adult survey on LCCs, an online survey through social media (i.e., Facebook, Instagram) to monitor trends in LCC use among youth and young adults ages 15 to 24 years. As soon as approvals are received, we will begin data collection for a national, online self-administered social media survey of approximately 750 youth per quarter, ages 15-17, and young adults ages 18-24. The survey will be repeated with a new cross-sectional sample approximately four times a year. The results of the vaping surveys and the LCC surveys will be used to inform specified recommendations around FDA's public education programs' impact and effectiveness in reducing tobacco-related death and disease.

The study aims to answer the following questions:

- What are the trends in brand and device use for vaping products among youth and young adults ages 15 to 24 years in the United States? What are their perceptions of these products?
- What are the reactions to proposed messages for media campaigns related to vaping products among youth and young adults ages 15 to 24 years in the United States?
- What are the trends in little cigar and cigarillo (LCC) use among youth and young adults ages 15 to 24 years in the United States? What are their perceptions of these products?
- What are the reactions to proposed messages for media campaigns related to LCCs among youth and young adults ages 15 to 24 years in the United States?

3. Use of Information Technology and Burden Reduction

This study will rely on web-based survey data collection to collect primary data to monitor youth and young adult perceptions on emerging trends in vaping products and LCCs. Using an online survey allows the respondent to be candid with their responses. This increases accuracy of the data because respondents provide more honest responses than when other types of data collection methods are employed, especially when it is clear that the answers will remain private. In addition, using a survey will allow for more participants to respond in a cost-effective and timely manner. The self-administered, web-based survey permits greater expediency with respect to data processing and analysis (e.g., a number of back-end processing steps, including coding and data entry). Data are transmitted electronically, rather than by mail. These efficiencies save time due to the speed of data transmission, as well as receipt in a format suitable for analysis. An added benefit is increased data protection by limiting the

amount of personally identifiable information (PII) collected from participants, reducing the risk of data security issues. Finally, as noted above, this technology permits respondents to complete the survey in privacy. The use of a more private data collection method makes reporting potentially embarrassing or stigmatizing behaviors (e.g., tobacco use) less threatening and enhances response validity and response rates.

4. Efforts to Identify Duplication and Use of Similar Information

With so many tobacco and vaping products on the market, it is important to develop messages that incorporate tobacco products currently being used by at-risk populations in order to be salient and have the best chance of affecting change in tobacco use. In designing the proposed data collection activities, we took several steps to ensure that this effort does not duplicate ongoing efforts and that no existing data sets would address the proposed study questions. We carefully reviewed existing data sets to determine whether any of them are sufficiently similar or could be modified to address FDA's need for information on emerging tobacco product use. Data sources we examined for this purpose include ongoing national surveillance systems such as the National Youth Tobacco Survey (NYTS), the Youth Risk Behavior Surveillance System (YRBSS), the National Health Interview Survey (NHIS), and the Population Assessment of Tobacco and Health (PATH). We also reviewed data collected to evaluate other national tobacco-focused media campaigns such as CDC's Tips From Former Smokers campaign and FDA's The Real Cost. We concluded that these data sources do not include the measures, and frequency of data collection, needed to monitor and track emerging trends in youth and young adult tobacco product use and perceptions on tobacco products, specifically for vaping products and LCCs. Although the other data sources measure youth and young adult tobacco use, including some popular brands, they do not include measures that would allow us to track which existing and new products are trending in the target population, which is necessary to inform the FDA's campaign development.

5. Impact on Small Businesses or Other Small Entities

Respondents in this study will be members of the general public, specific subpopulations or specific professions, not business entities. No impact on small businesses or other small entities is anticipated.

6. Consequence of Collecting the Information Less Frequently

Respondents to this data collection will answer only once in a six-month period to ensure the participant burden is as low as possible. Without the data collection requested for this study, it would be difficult to identify trends in the rapidly changing consumer environment for tobacco products and assess the types of effective messages for use in upcoming tobacco prevention campaigns. Failure to collect these data could reduce effectiveness of the FDA's messaging, and therefore reduce the benefit of the messages for youth in the United States.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances for this collection of information that require the data collection to be conducted in a manner inconsistent with 5 CFR 1320.5(d)(2). The message testing activities fully comply with the guidelines in 5 CFR 1320.5.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside Agency

The following individuals inside the agency have been consulted on the design of the study, instrument development, or intra-agency coordination of information collection efforts:

Tesfa Alexander
Office of Health Communication & Education
Center for Tobacco Products
Food and Drug Administration
9200 Corporate Boulevard
Rockville, MD 20850
Phone: 301-796.9335
E-mail: Tesfa.Alexander@fda.hhs.gov

Morgane Bennett
Office of Health Communication & Education
Center for Tobacco Products
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: 240-402-9281
E-mail: Morgane.Bennett@fda.hhs.gov

FDA collaborates with other federal government agencies that sponsor or endorse health communication projects, such as the Centers for Disease Control and Prevention, Office on Smoking and Health (CDC/OSH), the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institutes of Health National Cancer Institute (NIH/NCI). These affiliations serve as information channels, help prevent redundancy, and promote use of consistent measures of effectiveness. Coordination activities include:

- Review of proposed messages for advertisements;
- Review of questionnaires for testing purposes;
- Sharing data; and
- Standardizing survey tools where at all possible.

The following individuals outside of the agency have been consulted on questionnaire development.

Nathaniel Taylor
RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709
Phone: 919-316-3523
Email: ntaylor@rti.org

Jennifer Duke
RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709
Phone: 919-485-2269
E-mail: jduke@rti.org

Jane Allen
RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709
Phone: 919-597-5115
E-mail: Janeallen@rti.org

Matthew Farrelly
RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709
Phone: 919-541-6852
E-mail: mcf@rti.org

Laurel Curry
RTI International
3040 Cornwallis Road
Research Triangle Park, NC 27709
Phone: 202-728-2086
E-mail: lcurry@rti.org

9. Explanation of Any Payment or Gift to Respondents

As a token of appreciation, participants recruited through social media who complete and submit the full survey will receive a \$5 digital Amazon gift card, which reflects the burden of spending an estimated average time of 12 minutes taking the survey. Participants will be eligible to take the youth and young adult vaping survey or the youth and young adult LCC survey once every six months. There is no token of appreciation for completing the web screener. Participants will be informed that they will receive their token of appreciation within 5-7 business days of completing the survey.

The token of appreciation allows us to treat participants justly and with respect by acknowledging competing demands for their time and the effort they spend participating. The contractor executing this study, RTI, has experience conducting over 65 different recruitment campaigns with more than 20,000 participants using social media data collection, and has found a token of appreciation to be necessary to minimize non-response bias, complete data collection goals in a timely manner, reduce overall burden, and reduce costs.

10. Assurance of Confidentiality Provided to Respondents

Generic 0910-0810 is covered underneath an approved umbrella PIA.

PII Collection

As part of this study, RTI International, the contractor acting on behalf of FDA, is collecting and maintaining personally identifiable information (PII) about participants who complete the online screener and the online surveys. The only PII we will be collecting is email address, IP address, and birthdate, but this information will be stored separately from each other and from survey responses (except for 24 hours after download when the fraud detection procedures are completed). We are not collecting any Protected Health Information, defined as “Personally identifiable information that relates to a person's health, medical treatment or payment, and which was obtained from a "covered entity" (health care provider, health plan, or healthcare clearinghouse), as defined by HIPAA (Health Insurance Portability and Accountability Act) regulations.” Survey data will be kept separate from PII and/or stored on the Federal Information Processing Standards (FIPS) 199 except for the 24-hour period after download when the combined dataset is stored temporarily on the study share drive so that the fraud detection procedures can be conducted.

This study is funded by the FDA, a Department of Health and Human Services supported agency, and is covered by a Certificate of Confidentiality (CoC). Section 2012 of the 21st Century Cures Act includes significant amendments, to the previous statutory authority for such protections, to enhance privacy protections for individuals who are the subjects of federally funded research, under subsection 301(d) of the Public Health Service Act (42 U.S.C. 241). Specifically, the amended authority requires the FDA to issue a CoC to investigators or institutions engaged in research funded by the Federal government to protect the privacy of individuals who are subjects of this research. We will notify participants in the consent form of the protections that the Certificate provides.

Overview of Data Collection System

All information will be collected electronically through a self-administered survey instrument hosted in a secure, online, web-based data collection system. Approximately 21,000 participants will be recruited via social media. All participants will be screened for eligibility prior to administration of the survey instrument. The screener is designed to not reveal specifically why a respondent is not eligible. All respondents, regardless of age, gender, race/ethnicity, tobacco use behavior, and residence will complete the full screener.

Respondents must complete all screener questions to find out whether they can move on to one of the monthly monitoring surveys. To recruit for the first survey, RTI will place ads on Facebook and Instagram. As much as possible, these ads will target potentially eligible respondents who are thought to be age 15-24 and are ever users or susceptible to vaping. To recruit for the second survey, RTI will place ads on Facebook and Instagram. As much as possible, these ads will target potentially eligible respondents who are thought to be age 15-24 and susceptible to or ever users of LCCs. For the vaping surveys, we will screen respondents for eligibility through their age and tobacco use behavior (i.e., susceptible to, or ever users of, vaping products). For the LCC surveys, we screen for age and tobacco use behavior (i.e., susceptible to, or ever users of, LCCs).

Each participant will give feedback on their vaping or tobacco use status, followed by a series of questions about their knowledge, attitudes, and behaviors in regard to specific tobacco products and marijuana, and complete the survey by answering basic demographic information. The participant will complete the survey at the time of his or her choosing. There is no website content directed at children younger than 13 years of age.

Overview of How Information will be Shared and for What Purposes

All data will be downloaded from Qualtrics (which requires a password) and stored in databases only on RTI's secure shared drive and/or Federal Information Processing Standards (FIPS) 199, which are only accessible by study staff trained in human subjects. At the completion of data collection, the databases will be deleted from our Qualtrics account and remain only on RTI's secure shared drive and Federal Information Processing Standards (FIPS) 199.

Overview of the Impact the Proposed Collection will have on the Respondent's Privacy

The following procedures will be used to ensure participant privacy before, during, and after fielding: (1) PII in the form of participants' email addresses and birthdate will be stored separately from screening-related data and survey data, and email addresses and birthdate will be deleted after survey completion; (2) datasets and reports will not contain any PII; and (3) respondents' information will not be tied to their individual responses and all analyses will be conducted in the aggregate (i.e., any data used in reporting will not be attributed to individual participants). All datasets and reports delivered to FDA will not include PII.

PII will be collected in the form of email addresses for the purposes of distributing the token of appreciation and birthdate to confirm age. No additional personal identifiers (e.g., full name, phone number, social security number) will be collected aside from basic demographic information (e.g., gender, age, and race). Other than the participant's email address, no other social media profile identifiers will be collected through the social media recruitment. PII will be stored separately from any survey responses.

Overview of Voluntary Participation

Potential participants will be advised of the nature of the survey, the length of time it will require, and that participation is voluntary. Participants will be assured that they will incur no penalties if they wish not to respond to the data collection as a whole or to any specific questions. Participants will have the option to decline to respond to any item in the survey for any reason and may drop out of the survey at any time. These procedures conform to ethical practices for collecting data from human participants.

Overview of Data Security

E-mail addresses and birthdate will each be collected separately in the Qualtrics survey platform and stored in separate isolated surveys that will contain a RTI-assigned unique ID and email address or birthdate. IP address will be collected in the survey platform in an isolated survey that contains IP address, RTI-assigned unique ID, and screener responses. Responses to the body of the survey will be collected in the Qualtrics survey platform and stored in an isolated survey. IP address, e-mail address, and birthdate will not be collected in the same file.

All four survey data files (IP address, e-mail, birthdate, and survey responses) will be downloaded separately from Qualtrics (which requires a password). Since the Federal Information Processing Standards (FIPS) 199 does not permit access to the internet (and downloading the data from Qualtrics requires an internet connection), the four files will be downloaded to the secure RTI study share drive and stored on the study share drive for no more than 24 hours after download. Study staff will be given as-needed access to the data files on the share during that 24-hour period to conduct fraud detection procedures, at which point data from the individual will be combined to check for fraudulent responses.

At the end of data collection, a member of the project staff will export the data from the survey and out of the Federal Information Processing Standards (FIPS) 199, saving them directly onto the project share drive. Only RTI project staff directly involved in programming, sampling, recruitment, or analysis will have access to the survey data or sampling frame. No respondent identifiers will be contained in reports to FDA, and results will only be presented in aggregate form.

11. Justification for Sensitive Questions

The majority of questions asked will not be of a sensitive nature. However, it will be necessary to ask some questions that may be considered to be of a sensitive nature in order to assess specific health behaviors such as tobacco product use, separately from marijuana use. These questions are essential to the objectives of this data collection. Although we do not anticipate any risks from these health questions, some participants may perceive them to be sensitive. Questions about messages concerning lifestyle (e.g., current marijuana and tobacco product use) and some demographic information, such as race and ethnicity could also be considered sensitive, but not highly sensitive. To address any concerns about inadvertent disclosure of sensitive information, participants will be fully informed of the applicable privacy safeguards.

The informed consent protocol will notify participants that these topics will be covered in the survey. This study includes a number of procedures and methodological characteristics that will minimize potential negative reactions to these types of questions, including the following:

- Participants will be informed that they need not answer any question that makes them feel uncomfortable or that they simply do not wish to answer;
- Web surveys are entirely self-administered and maximize respondent privacy without the need to verbalize responses; and
- Participants will be provided with a phone number and email address for the Principal Investigator should they have any questions or concerns about the study.

12. Estimates of Annualized Burden Hours and Costs

12 a. Annualized Hour Burden Estimate

An estimated one-time reporting burden for this collection will be approximately 6,826 hours (Table 1). This includes the time burden associated with the screener and informed consent. We will obtain a final sample size of 21,000 youth and young adults. Data collection will be split among two surveys. Survey One: We will survey approximately 18,000 individuals (approximately 1,500 youth, ages 15-17, and young adults ages 18-24 each month for 12 months) to monitor perceptions about vaping products and other emerging tobacco products. Respondents will be allowed to complete additional, cross-sectional surveys after 6 months. Survey Two: We will survey approximately 3,000 youth and young adults ages 15 to 24 years (approximately 750 participants with a new cross-sectional sample four times a year) to monitor trends in LCC use. Respondents will be allowed to complete an additional, cross-sectional survey after 6 months. We will need to screen approximately 42,000 potential participants for both surveys.

Table 1. Estimated Annual Reporting Burden¹

Type of Respondent	Activity	Number of Respondents	Number of Responses per Respondent	Total Responses	Average Burden per Response (in hours)	Total Hours ¹
Screening						
Youth aged 15–17	Youth Recruiting and Screening	21,000	1	21,000	0.04 (2.5 minutes)	875
Young Adult aged 18-24	Adult Recruiting and Screening	21,000	1	21,000	0.04 (2.5 minutes)	875
Informed Consent						
Youth aged 15–17	Youth Assent	10,500	1	10,500	0.04 (2.5 minutes)	438
Young Adult aged 18-24	Adult Consent	10,500	1	10,500	0.04 (2.5 minutes)	438
Survey						

Youth aged 15–17	Online Survey	10,500	1	10,500	0.20 (12 minutes)	2,100
Young Adult aged 18-24	Online Survey	10,500	1	10,500	0.20 (12 minutes)	2,100
Total Annualized Hours						6,826

12b. Annualized Cost Burden Estimate

Respondents participate on a purely voluntary basis and, therefore, are subject to no direct costs other than time to participate. There are also no start-up or maintenance costs. RTI has conducted many smoking-related surveys of similar length among youth and adults. We have examined diagnostic data from prior surveys and estimate that data collection for this study will take approximately 2.5 minutes per respondent for screening, 2.5 minutes per respondent for assenting/consenting, and approximately 12 minutes per respondent for the online surveys.

To calculate the estimate annual cost, the mean hourly wage of \$7.25 was used for youth and \$26.95 was used for young adults. The youth price represents the minimum wage, and the young adult costs represent the mean hourly wage for other occupation earnings from the U.S. Department of Labor Bureau of Labor Statistics (May 2020 data). There are no direct costs to respondents associated with participation in this information collection. RTI has conducted many smoking-related surveys of similar length among youth and adults. We have examined diagnostic data from each of these prior surveys and estimate that data collection for this study will take, on average, 2.5 minutes per respondent for screening, 2.5 minutes per respondent for assenting/consenting, and approximately 12 minutes per respondent for the online surveys. Thus, assuming an average hourly wage of \$7.25 and \$26.95 (youth and young adult), the estimated one-year annualized cost to participants will be \$116,725. The estimated value of respondents' time for participating in the information collection is summarized in Table 2.

Table 2. Estimated Annual Cost

Type of Respondent	Activity	Annual Burden Hours	Hourly Wage Rate	Total Cost ¹
Youth aged 15–17	Youth Recruiting and Screening	875	\$7.25	\$6,344
	Youth Assent	438	\$7.25	\$3,176
	Online Survey	2,100	\$7.25	\$15,225
Young Adult aged 18-24	Adult Recruiting and Screening	875	\$26.95	\$23,581
	Adult Consent	438	\$26.95	\$11,804
	Adult Survey	2,100	\$26.95	\$56,595
Total				\$116,725

¹ Cost was rounded up to the next dollar.

13. Estimates of Other Total Annual Cost Burden to Respondents or Record Keepers

There are no capital, start-up, operating, or maintenance costs associated with this data collection.

14. Annualized Cost to the Federal Government

This information collection is funded through a contract with RTI. The estimated costs attributable to this data collection are \$753,587 per year. (Table 3). There are additional contract-funded activities occurring before and after this data collection that include project planning and data analysis. Other activities outside this data collection include coordination with FDA, instrument development, reporting, RTI IRB, project management and progress reporting. This information collection will occur from 2020 through 2021.

Table 3. Itemized Cost to the Federal Government

Government Personnel	Time Commitment	Average Annual Salary	Total¹
GS-12	5%	\$86,335	\$4,317
GS-13	10%	\$102,663	\$10,266
GS-13	10%	\$102,663	\$10,266
		Total Annual Salary Costs	\$24,849
Annual Contract Cost			\$728,738
Total Annual Cost			\$753,587

¹ Cost was rounded up to the next dollar.

15. Explanation for Program Changes or Adjustments

This is a new individual generic data collection.

16. Plans for Reporting and Project Time Schedule

Data from this information collection will be used to enable the FDA to identify, monitor, assess, or investigate vaping and other tobacco product use. This activity will allow the FDA to set priorities and raise situational awareness because vaping and the use of other tobacco products are a threat to public health. These data will allow us to track and determine trends in tobacco brand and device choices so that the FDA can develop new media campaign messages related to tobacco and vaping products that resonate with youth and young adults ages 15 to 24 years old in the United States. Findings from these analyses will be used to inform FDA CTP health communication strategy and messaging.

Reporting

Reporting will consist of monthly summaries of key results and findings. At the end of the study, a draft report and a final report containing background information on the project objectives, scope and methodology, and key findings and conclusions will be completed. The approximate dates for completing project tasks are listed in Table 4.

Table 4. Approximate Project Schedule

Project Activity	Date
Survey	September 2020 to September 2021 (Approximate)
Preparation of analytic data file	Approximately 1–2 weeks after completion of data collection
Data Analysis	Approximately 3–5 weeks after completion of data collection
Report Writing	Approximately 6-8 weeks after completion of data collection

17. Reason(s) Display of OMB Expiration Date is Inappropriate

Not applicable. All data collection instruments will display the expiration date for OMB approval of the information collection.

18. Exceptions to Certification for Paperwork Reduction Act Submissions

These information collection activities involve no exception to the Certification for Paperwork Reduction Act Submissions.

References

- Dai, H., & Leventhal, A. (2019). Prevalence of e-cigarette use among adults in the United States, 2014-2018. *JAMA*. 322(18), 1824-1827.
- Kasza, K., Ambrose, B., Conway, K., et al. (2017). Tobacco-product use by adults and youths in the United States in 2013 and 2014. *N. Engl J. Med.* 376(4), 342-353.
- Wang, T., Gentzke, A., Creamer, M., et al. (2019). Tobacco product use and associated factors among middle and high school students – United States, 2019. *Morbidity and Mortality Weekly Report*. 68(12).